Literature DB >> 6348062

Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids in acquired total lipodystrophy: effects on hyperlipoproteinemia and endogenous insulin resistance.

D E Wilson, I F Chan, K B Stevenson, S C Horton, C Schipke.   

Abstract

Previous studies have suggested that reduction of dietary fat intake, with or without caloric restriction, may lead to improvement in certain of the characteristic abnormalities that accompany total lipodystrophy (TLD). We have studied the effects of eucaloric medium chain triglyceride (MCT) substitution for dietary long chain fatty acids in a patient with acquired total lipodystrophy and unusual somatic and visceral anomalies. The patient exhibited insulin resistance, carbohydrate intolerance, striking fasting- and glucose-stimulated hyperinsulinemia, hyperglucagonemia, type V hyperlipoproteinemia, and lipoprotein lipase deficiency on a normal diet. Improvement in chylomicronemia, hypertriglyceridemia, and xanthomatosis occurred during eucaloric MCT substitution. Carbohydrate intolerance decreased and fasting immunoreactive glucagon and insulin concentrations fell 37% and 83%, respectively. Plasma triglyceride polyunsaturated fatty acid concentrations decreased to very low levels. With long term MCT feeding supplemented by polyunsaturated fatty acids, hepatomegaly has gradually decreased, while body weight has remained stable. The patient has not yet required insulin therapy. These observations suggest that the abnormalities in carbohydrate metabolism are closely linked to, and perhaps dependent on, the abnormalities in lipoprotein transport in TLD. Long chain triglyceride restriction and MCT supplementation should be attempted in additional patients with the features of TLD to determine whether this is a generally effective therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6348062     DOI: 10.1210/jcem-57-3-517

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Lipodystrophy: pathophysiology and advances in treatment.

Authors:  Christina G Fiorenza; Sharon H Chou; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 2.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

3.  Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases.

Authors:  Stephanie Teboul-Coré; Caroline Rey-Jouvin; Anne Miquel; Camille Vatier; Jacqueline Capeau; Jean-Jacques Robert; Thao Pham; Olivier Lascols; Francis Berenbaum; Jean-Denis Laredo; Corinne Vigouroux; Jérémie Sellam
Journal:  Skeletal Radiol       Date:  2016-09-08       Impact factor: 2.199

Review 4.  Lipodystrophy syndromes.

Authors:  Pedro Herranz; Raul de Lucas; Luis Pérez-España; Matias Mayor
Journal:  Dermatol Clin       Date:  2008-10       Impact factor: 3.478

5.  Case report: unicameral bone cysts in a young patient with acquired generalized lipodystrophy.

Authors:  James M Gregory; Alexandre Arkader; Aqiba Bokhari; Aqiba Bothari; John P Dormans
Journal:  Clin Orthop Relat Res       Date:  2009-11-19       Impact factor: 4.176

Review 6.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

Authors:  Rebecca J Brown; David Araujo-Vilar; Pik To Cheung; David Dunger; Abhimanyu Garg; Michelle Jack; Lucy Mungai; Elif A Oral; Nivedita Patni; Kristina I Rother; Julia von Schnurbein; Ekaterina Sorkina; Takara Stanley; Corinne Vigouroux; Martin Wabitsch; Rachel Williams; Tohru Yorifuji
Journal:  J Clin Endocrinol Metab       Date:  2016-10-06       Impact factor: 5.958

Review 7.  Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicity.

Authors:  Mark F McCarty; James J DiNicolantonio
Journal:  Open Heart       Date:  2016-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.